95% Premium Sooner, I had to post this because it does happen occasionally. Yea it's biotech but that's an amazing premium they're paying. I guess it just depends on how bad a company wants something they don't have or control. We can't give Rio any more cheap shares...
Per the deal terms, AbbVie will pay ImmunoGen $31.26 per share in cash, which adds up to a total equity value of approximately $10.1 billion. The purchase price of $31.26 represents quite a rich premium of almost 95% on ImmunoGen’s closing price of $16.06 on Nov 29.